Ceftriaxone (Rocephin)
ceftriaxone sodium
Indications
| Indication | Key Pathogens | Therapy Type | Status |
|---|---|---|---|
| Lower respiratory tract infections | S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, E. coli, Enterobacter, Proteus, Serratia | Monotherapy | FDA Approved |
| Acute bacterial otitis media | S. pneumoniae, H. influenzae, M. catarrhalis | Monotherapy (single IM dose) | FDA Approved |
| Skin & skin structure infections | S. aureus, S. pyogenes, E. coli, K. pneumoniae, B. fragilis, Peptostreptococcus | Monotherapy | FDA Approved |
| UTI (complicated & uncomplicated) | E. coli, P. mirabilis, P. vulgaris, M. morganii, K. pneumoniae | Monotherapy | FDA Approved |
| Uncomplicated gonorrhea | N. gonorrhoeae | Monotherapy (single IM dose) | FDA Approved |
| Pelvic inflammatory disease | N. gonorrhoeae (add antichlamydial coverage) | Combination | FDA Approved |
| Bacterial septicemia | S. aureus, S. pneumoniae, E. coli, H. influenzae, K. pneumoniae | Monotherapy or combination | FDA Approved |
| Bone & joint infections | S. aureus, S. pneumoniae, E. coli, P. mirabilis, K. pneumoniae, Enterobacter | Monotherapy | FDA Approved |
| Intra-abdominal infections | E. coli, K. pneumoniae, B. fragilis, Clostridium spp., Peptostreptococcus | Monotherapy or combination | FDA Approved |
| Meningitis | H. influenzae, N. meningitidis, S. pneumoniae | Monotherapy or combination | FDA Approved |
| Surgical prophylaxis | Contaminated/potentially contaminated procedures | Prophylaxis (single dose) | FDA Approved |
Ceftriaxone is a third-generation cephalosporin distinguished by its exceptionally long half-life (5.8–8.7 hours), permitting once-daily dosing for most infections. It has broad gram-negative activity including beta-lactamase-producing organisms, useful gram-positive coverage (MSSA, streptococci), and some anaerobic activity. It penetrates the CSF effectively with inflamed meninges, making it a cornerstone agent for bacterial meningitis. Its dual biliary-renal excretion eliminates the need for renal dose adjustment in most patients. Current CDC guidelines recommend ceftriaxone 500 mg IM as the preferred regimen for uncomplicated gonorrhea.
Lyme disease (disseminated/late): Ceftriaxone 2 g IV daily for 14–28 days is the IDSA/AAN-recommended regimen for Lyme neuroborreliosis, Lyme carditis with AV block, and Lyme arthritis refractory to oral therapy. Evidence quality: High.
Infective endocarditis (native valve, streptococcal): AHA guidelines recommend ceftriaxone 2 g IV Q24H × 4 weeks (with or without gentamicin) for penicillin-susceptible viridans streptococcal or S. bovis endocarditis. Evidence quality: High.
Spontaneous bacterial peritonitis (SBP): AASLD guidelines recommend ceftriaxone 2 g IV Q24H as empiric therapy for SBP in hospitalised cirrhotic patients. Evidence quality: Moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| General infections (LRTI, UTI, SSSI, intra-abdominal) | 1–2 g IV/IM Q24H | 1–2 g IV/IM Q24H or divided BID | 4 g/day | 4–14 days; continue ≥2 days after symptoms resolve Once-daily dosing is standard due to long half-life |
| Bacterial meningitis | 2 g IV Q12H | 2 g IV Q12H | 4 g/day | 7–14 days; empiric: combine with vancomycin + ampicillin IDSA meningitis guideline: add vancomycin for suspected S. pneumoniae |
| Uncomplicated gonorrhea (cervical, urethral, rectal) | 500 mg IM single dose | N/A | 500 mg | CDC 2020 updated recommendation FDA PI lists 250 mg; CDC increased to 500 mg in 2020 |
| Pelvic inflammatory disease | 500 mg IM single dose | N/A | 500 mg | Plus doxycycline ± metronidazole for full coverage CDC 2021 updated to 500 mg; FDA PI lists 250 mg; no activity against C. trachomatis |
| Bacterial septicemia / bone & joint | 1–2 g IV Q24H | 2 g IV Q24H or Q12H | 4 g/day | Duration based on source; bone/joint: 4–6 weeks |
| Surgical prophylaxis | 1 g IV single dose | N/A | 1 g | Give ½–2 hours before surgery |
| Acute bacterial otitis media (pediatric) | 50 mg/kg IM single dose | N/A | 1 g | Reserve for failed oral therapy or unable to take oral |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Skin/SSSI and general infections | 50–75 mg/kg/day | QD or divided Q12H | 2 g/day | For non-meningitis infections |
| Meningitis | 100 mg/kg IV loading dose | 100 mg/kg/day QD or divided Q12H | 4 g/day | 7–14 days; infuse over 30 min (60 min in neonates) |
Ceftriaxone must NOT be administered simultaneously with calcium-containing IV solutions in ANY patient. In neonates (≤28 days), ceftriaxone is contraindicated if the patient requires calcium-containing IV solutions (including TPN) because fatal ceftriaxone-calcium precipitates in the lungs and kidneys have been reported. In patients other than neonates, sequential administration is permitted only if infusion lines are thoroughly flushed between infusions. Neonatal IV infusions should be given over 60 minutes to reduce the risk of bilirubin encephalopathy (FDA PI).
Ceftriaxone is unique among injectable cephalosporins in that it undergoes dual elimination — approximately 33–67% is excreted unchanged in urine and the remainder through biliary secretion. This compensatory pathway means that standard dosing (up to 2 g/day) can be maintained even in severe renal impairment, and ceftriaxone is not removed by hemodialysis or peritoneal dialysis. The only exception is combined severe renal AND hepatic impairment, where the daily dose should not exceed 2 g with monitoring of serum concentrations.
Pharmacology
Mechanism of Action
Ceftriaxone is a bactericidal beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting the final transpeptidation step of peptidoglycan cross-linking. As a third-generation cephalosporin, it has enhanced stability against a broad range of beta-lactamases including those produced by Enterobacteriaceae, which extends its gram-negative spectrum compared with first- and second-generation agents. Its bactericidal activity is time-dependent (% fT > MIC), though the long half-life means that even once-daily dosing maintains adequate free drug concentrations above the MIC for most susceptible organisms throughout the dosing interval. Ceftriaxone has no activity against MRSA, enterococci, Listeria, or atypical pathogens.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Not orally bioavailable; 100% absorbed IM (Tmax 2–3 h); Cmax ~151 mcg/mL after 1 g IV (0.5 h); ~76 mcg/mL after 1 g IM (2 h) | IM administration practical for outpatient settings (e.g., gonorrhea, Lyme disease OPAT) |
| Distribution | Vd 5.78–13.5 L; protein binding 85–95% (concentration-dependent: 95% at 25 mcg/mL, 85% at 300 mcg/mL); penetrates CSF (5.6–6.4 mcg/mL in meningitis), middle ear fluid (t½ 25 h), bile (>580 mcg/mL), bone, placenta | High protein binding is saturable at therapeutic concentrations; excellent CSF and biliary penetration supports meningitis and biliary infection use; displaces bilirubin from albumin (neonatal risk) |
| Metabolism | Not hepatically metabolized; drug excreted in bile is degraded to microbiologically inactive compounds by intestinal flora | No CYP450 involvement; no hepatic dose adjustment needed unless combined with severe renal disease |
| Elimination | t½ 5.8–8.7 h (adults); 33–67% excreted unchanged in urine, remainder via bile; renal clearance 0.32–0.73 L/h; NOT removed by hemodialysis or peritoneal dialysis | Long half-life enables once-daily dosing; dual elimination pathway eliminates need for renal dose adjustment; 15–36% accumulation with repeated dosing |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Eosinophilia | 6% | Usually transient; does not require dose change |
| Thrombocytosis | 5.1% | Generally not clinically significant |
| ALT elevation | 3.3% | Transient; monitor if prolonged therapy |
| AST elevation | 3.1% | Transient hepatic enzyme changes |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea / loose stools | 2.7% | Distinguish from C. difficile; may require evaluation |
| Leukopenia | 2.1% | Monitor CBC in prolonged courses |
| Rash | 1.7% | Evaluate for evolving hypersensitivity |
| BUN elevation | 1.2% | May indicate ceftriaxone-calcium renal precipitation; ensure hydration |
| Phlebitis (IV) / injection site pain (IM) | ~1% | IM 350 mg/mL: 17% induration; 250 mg/mL: 5%; use lidocaine for IM reconstitution |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Anaphylaxis / severe hypersensitivity | Rare | Minutes to hours | Discontinue; epinephrine; emergency care |
| Immune-mediated hemolytic anemia | Rare (fatalities reported) | During therapy | Stop ceftriaxone; evaluate for cephalosporin-associated hemolysis; transfuse if needed |
| Gallbladder pseudolithiasis (biliary sludge) | Uncommon (higher in pediatrics) | Days to weeks | Usually asymptomatic; discontinue if symptomatic gallbladder disease develops; reversible on stopping |
| Urolithiasis / post-renal acute renal failure | Rare (higher in pediatrics) | During therapy | Ensure adequate hydration; discontinue if oliguria, renal failure, or sonographic abnormalities develop |
| Pancreatitis (secondary to biliary obstruction) | Rare | During therapy | Discontinue; supportive care; risk factors include TPN, severe illness |
| C. difficile-associated diarrhea | Uncommon | During or up to 2 months post-therapy | Test for toxin; discontinue ceftriaxone; treat with vancomycin or fidaxomicin |
| Ceftriaxone-calcium precipitation (neonates) | Rare (fatal cases in neonates) | During co-administration with calcium | NEVER co-administer with calcium IV in neonates; see Contraindications |
| Stevens-Johnson syndrome / TEN | Very rare (postmarketing) | 1–3 weeks | Discontinue immediately; dermatology referral |
Drug Interactions
Ceftriaxone undergoes no CYP-mediated metabolism. Its most critical interaction is the physicochemical precipitation with calcium in IV solutions. Probenecid does not alter ceftriaxone elimination, which is unique among cephalosporins.
Monitoring
- Clinical Response48–72 h
RoutineAssess for clinical improvement. Repeat blood cultures at 48–72 h for bacteremia. For meningitis, consider repeat LP if not improving. - CBCWeekly if therapy >7 days
RoutineMonitor for eosinophilia (6%), leukopenia (2.1%), thrombocytopenia, hemolytic anemia. Agranulocytosis reported after >10 days / >20 g cumulative dose. - Hepatic FunctionBaseline; periodically
RoutineAST (3.1%) and ALT (3.3%) elevations common; usually transient. Monitor bilirubin in patients with combined renal-hepatic impairment. - Renal FunctionBaseline; if concurrent renal/hepatic disease
Trigger-basedStandard doses usually safe even in severe renal impairment. Cap at 2 g/day and monitor drug levels if combined severe renal AND hepatic dysfunction. - PT/INRDuring therapy if on anticoagulants
Trigger-basedMonitor prothrombin time in patients on warfarin, with hepatic disease, malnutrition, or prolonged courses. Administer vitamin K 10 mg weekly as indicated. - Biliary SonographyIf RUQ symptoms develop
Trigger-basedCeftriaxone-calcium biliary precipitates may appear as sludge or pseudolithiasis on ultrasound. Usually asymptomatic and reversible on discontinuation. - Hydration / Urine OutputThroughout therapy
RoutineEnsure adequate hydration to minimize risk of ceftriaxone-calcium urinary precipitation and nephrolithiasis, especially in pediatric patients.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to ceftriaxone, any cephalosporin, or excipients
- Premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age)
- Hyperbilirubinemic neonates — ceftriaxone displaces bilirubin from albumin, risking bilirubin encephalopathy
- Neonates (≤28 days) requiring calcium-containing IV solutions (including TPN) — fatal ceftriaxone-calcium precipitates reported
- IV administration of lidocaine-containing ceftriaxone solutions
Relative Contraindications (Specialist Input Recommended)
- History of penicillin or beta-lactam allergy — patients may be at greater risk of hypersensitivity to ceftriaxone
- Combined severe renal AND hepatic impairment — cap dose at 2 g/day; monitor serum concentrations
Use with Caution
- History of GI disease (especially colitis) — increased risk of C. difficile
- Patients receiving concurrent calcium-containing IV products (non-neonates) — sequential administration only with thorough line flush
- Patients on anticoagulants or with impaired vitamin K synthesis — monitor prothrombin time
- Pediatric patients on prolonged therapy — higher risk of biliary and renal ceftriaxone-calcium precipitation
Fatal outcomes in which crystalline ceftriaxone-calcium precipitates were observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone and calcium-containing fluids, in some cases via the same IV line and in others via different lines at different times. Ceftriaxone is contraindicated in neonates (≤28 days) who require or are expected to require calcium-containing IV solutions. In non-neonates, ceftriaxone and calcium solutions must never be given simultaneously but may be given sequentially if lines are thoroughly flushed (FDA PI, revised 2015).
Patient Counselling
Purpose of Therapy
Ceftriaxone is a strong prescription antibiotic given as an injection (into a vein or muscle) to treat serious bacterial infections, including infections of the lungs, blood, brain, bones, abdomen, and urinary tract. It is also used in a single injection to treat gonorrhea and to prevent infections during surgery. Ceftriaxone does not work against viral infections.
How It Is Given
Ceftriaxone is given by a healthcare professional as an intravenous infusion (over at least 30 minutes) or as an intramuscular injection. Most infections require one dose per day due to the drug’s long duration of action. Treatment duration depends on the type of infection — typically 4 to 14 days, with some serious infections (bone, endocarditis) requiring longer courses.
Sources
- Rocephin (ceftriaxone sodium) prescribing information. Roche. Revised 2015. FDA LabelPrimary source for all approved indications, dosing (adults and pediatric), PK data (Tables 1–4), adverse reactions with incidence rates, contraindications (including neonatal calcium restriction), and drug interactions.
- Ceftriaxone for injection prescribing information. Hospira/Pfizer. Pfizer LabelGeneric ceftriaxone label confirming identical clinical information to branded Rocephin product; includes updated prescribing guidance.
- Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr Infect Dis J. 2000;19(5 Suppl):S57-S65. doi:10.1097/00006454-200005001-00008Supports single-dose IM ceftriaxone as effective therapy for acute otitis media in pediatric patients.
- van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22(Suppl 3):S37-S62. doi:10.1016/j.cmi.2016.01.007European guideline recommending ceftriaxone 2 g Q12H as first-line empiric therapy for community-acquired bacterial meningitis in adults.
- Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284. doi:10.1086/425368IDSA meningitis guideline establishing ceftriaxone + vancomycin as empiric standard for community-acquired bacterial meningitis.
- St Cyr S, Barbee L, Workowski KA, et al. Update to CDC’s treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1911-1916. doi:10.15585/mmwr.mm6950a6CDC update increasing recommended ceftriaxone dose for uncomplicated gonorrhea from 250 mg to 500 mg IM as a single dose.
- Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296AHA guideline recommending ceftriaxone 2 g IV Q24H for 4 weeks as preferred therapy for penicillin-susceptible viridans streptococcal native valve endocarditis.
- Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease. Clin Infect Dis. 2006;43(9):1089-1134. doi:10.1086/508667IDSA guideline recommending ceftriaxone 2 g IV daily for 14–28 days for Lyme neuroborreliosis, Lyme carditis, and refractory Lyme arthritis.
- Runyon BA; AASLD. Introduction to the revised AASLD practice guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651-1653. doi:10.1002/hep.26359AASLD guideline supporting ceftriaxone as empiric therapy for spontaneous bacterial peritonitis in hospitalised cirrhotic patients.
- Neu HC, Meropol NJ, Fu KP. Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother. 1981;19(3):414-423. doi:10.1128/AAC.19.3.414Original characterisation of ceftriaxone in vitro activity against broad range of gram-positive and gram-negative organisms demonstrating beta-lactamase stability.
- Patel IH, Chen S, Parsonnet M, et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981;20(5):634-641. doi:10.1128/AAC.20.5.634Foundational human PK study establishing ceftriaxone half-life (6–9 h), concentration-dependent protein binding (85–95%), dual renal-biliary elimination, and basis for once-daily dosing.
- Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 1990;322(3):141-147. doi:10.1056/NEJM199001183220301Pivotal RCT demonstrating superiority of ceftriaxone over cefuroxime for pediatric bacterial meningitis, establishing ceftriaxone as preferred agent.